Bachem is continuously innovating in the manufacture of synthetic peptides.
The synthetic Active Pharmaceutical Ingredient (API) liraglutide is a remarkable example of Bachem's technical and analytical capabilities that help provide patients with safe and affordable generic medicines. In addition to liraglutide, we offer a portfolio of GLP-1 analogues.
We are increasing process efficiencies and using the latest manufacturing and purification technologies to deliver large volumes at a competitive price. We do not compromise product quality and adhere to the strictest regulatory guidelines. Product quality and patient safety always come first.
Featuring Sergey Malashikhin, Group Head of Sales, Generics, Bachem.
Contact the experts today: www.bachem.com...
---------------------------------------------------------------------------------------------------------------------------
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Learn more about our products and services at bit.ly/3LykCeY
28 авг 2024
